Patents by Inventor Debra Pittman

Debra Pittman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101998
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: November 24, 2020
    Publication date: April 8, 2021
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 10875929
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Publication number: 20200392205
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Application
    Filed: February 24, 2020
    Publication date: December 17, 2020
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Publication number: 20200190214
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: December 17, 2019
    Publication date: June 18, 2020
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 10570189
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 25, 2020
    Assignee: PFIZER INC.
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Patent number: 10550200
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 4, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Publication number: 20190231856
    Abstract: The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.
    Type: Application
    Filed: October 11, 2018
    Publication date: August 1, 2019
    Inventors: Steven Arkin, Marcus Carr, Joachim Fruebis, Sunita Hett, Reema Jasuja, Debra Pittman
  • Publication number: 20170073428
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 16, 2017
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Publication number: 20160375109
    Abstract: The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.
    Type: Application
    Filed: January 15, 2015
    Publication date: December 29, 2016
    Inventors: Steven Arkin, Marcus Carr, Joachim Fruebis, Sunita Hett, Reema Jasuja, Debra Pittman
  • Publication number: 20150306234
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Application
    Filed: March 4, 2015
    Publication date: October 29, 2015
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Publication number: 20090075884
    Abstract: Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.
    Type: Application
    Filed: July 17, 2008
    Publication date: March 19, 2009
    Applicant: GENETICS INSTITUTE, LLC
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
  • Publication number: 20070286858
    Abstract: Antibodies that bind specifically to receptor for advanced glycation end products (RAGE) and RAGE-binding fragments thereof are disclosed. Also disclosed are pharmaceutical compositions comprising such anti-RAGE antibodies and RAGE-binding antibody fragments thereof, and their use for treatment of RAGE related diseases.
    Type: Application
    Filed: March 21, 2007
    Publication date: December 13, 2007
    Applicant: Wyeth
    Inventors: Brian Clancy, Debra Pittman, Xiang-Yang Tan, Lioudmila Tchistiakova, Kodangattil Sreekumar, Janet Paulsen, Angela Widom, Nicole Piche-Nicholas, Ying Sun
  • Publication number: 20070274987
    Abstract: The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and/or ZB-1 activity, expression, and/or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides.
    Type: Application
    Filed: May 25, 2007
    Publication date: November 29, 2007
    Inventors: Valerie Clerin, Heather Shih, Kathleen Shields, Jeffrey Feldman, Gustave Hebert, Debra Pittman, Nanhua Deng
  • Patent number: 7226587
    Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 5, 2007
    Assignee: Wyeth
    Inventors: Brian Clancy, Debra Pittman, Howard Seeherman
  • Publication number: 20060140933
    Abstract: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.
    Type: Application
    Filed: August 18, 2003
    Publication date: June 29, 2006
    Applicant: Wyeth and Imperial College Innovations Limited
    Inventors: Debra Pittman, Brian Clancy, Glenn Larsen, William Trepicchio, Fionula Brennan, Marc Feldmann, Brian John Foxwell, Jeffrey Feldman
  • Publication number: 20060099186
    Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.
    Type: Application
    Filed: December 23, 2005
    Publication date: May 11, 2006
    Inventors: Brian Clancy, Debra Pittman, Howard Seeherman
  • Publication number: 20050244849
    Abstract: The invention provides methods for identifying, designing, and optimizing therapeutics for R.A using as targets one or more genes (and/or their encoded gene products) that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Methods and compositions for diagnostic assays for detecting R.A. are also provided.
    Type: Application
    Filed: December 16, 2004
    Publication date: November 3, 2005
    Applicant: Genetics Institute, LLC
    Inventors: Debra Pittman, Jeffrey Feldman, Kathleen Shields, William Trepicchio
  • Publication number: 20050238648
    Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
    Type: Application
    Filed: June 20, 2005
    Publication date: October 27, 2005
    Inventors: Kenneth Jacobs, Debra Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
  • Publication number: 20050214315
    Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 and related proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
    Type: Application
    Filed: January 14, 2005
    Publication date: September 29, 2005
    Applicant: GENETICS INSTITUTE, LLC
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret Golden-Fleet
  • Patent number: 6902735
    Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: June 7, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet